Novel pharmacologic approaches to the prevention and treatment of ulcerative colitis

Current Pharmaceutical Design

Volumn 19, Issue 1, 2013, Pages 17-28

  Deng, Xiaoming ^a   Szabo, Sandor ^a   Khomenko, Tetyana ^a   Tolstanova, Ganna ^a,c   Paunovic, Brankica ^a   French, Samuel W ^b   Sandor, Zsuzsanna ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

Author keywords

Angiogenesis; Angiogenic growth factors; BFGF; Histamine; Pathologic angiogenesis; PDGF; PlGF; Rac 1; Src kinase; Ulcer healing; Ulcerative colitis; Vascular permeability; VE cadherin; VEGF

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ANGIOGENIC FACTOR; BEVACIZUMAB; DIPHENHYDRAMINE; DOXANTRAZOLE; EPHRIN A1; FIBROBLAST GROWTH FACTOR 2; FOCAL ADHESION KINASE; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INFLIXIMAB; INTERLEUKIN 1; MEPYRAMINE; MESALAZINE; PL 14736; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; RAC1 PROTEIN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; SPHINGOSINE 1 PHOSPHATE; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CELL INFILTRATION; COLON MUCOSA; COLON ULCER; DISEASE COURSE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEALING IMPAIRMENT; HISTAMINE RELEASE; HUMAN; INFLAMMATORY CELL; MUCOSA INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; ULCER HEALING; ULCERATIVE COLITIS;

EID: 84873980012     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128130105     Document Type: Review

References (90)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-25.
2. Di Sabatino A, Biancheri P, Rovedatti L, Macdonald TT, Corazza GR. Recent advances in understanding ulcerative colitis. Intern Emerg Med 2011; Nov 9. [Epub ahead of print]
3. Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004; 126: 1533-49.
4. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-tomoderate left-sided UC or proctitis. N. Engl. J. Med. 2003; 349: 350-7.
5. Herrinton L J, Liu L, Lewis JD, Griffin PM, and Allison J. Incidence and prevalence of inflammatory bowel disease in Northern California Managed Care Organization, 1996-2002. Am J Gastroenterol 2008; 103: 1998-2006.
6. Szabo S, Folkman J, Vattay P, Morales RE, Pinkus GS, Kato K. Accelerated healing of duodenal ulcers by oral administration of a mutein of basic fibroblast growth factor in rats. Gastroenterology 1994; 106: 1106-11.
7. Szabo S, Sakoulas G, Kusstatscher S, Sandor Zs. Effects of endogenous and exogenous basic fibroblast growth factor in ulcer healing. Eur J Gastroenterol 1993; 5: S53-7.
8. Szabo S, Sandor Zs. Basic fibroblast growth factor and PDGF in GI diseases. In: Goodlad R.A. Wright NA, Eds. Bailliere's Clinical Gastroenterology. London: WB Saunders; 1996; pp. 97-112.
9. Szabo S, Vincze A, Sandor Zs, et al. Vascular approach to gastroduodenal ulceration. New studies with endothelins and VEGF. Dig Dis Sci 1998; 43: S40-5.
10. Tolstanova G, Khomenko T, Deng XM, et al. Neutralizing anti-VEGF antibody reduces severity of experimental ulcerative colitis in rats. Direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328: 749-57.
11. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060-73.
12. Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: New ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007; 293: G5-18.
13. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136: 585-95.
14. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007; 14: 1860-9.
15. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 1411-6.
16. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44: 1-9.
17. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008; 11: 215-21.
18. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-75.
19. Sandor Z, Kusstatscher S, Szeli D, Szabo S. Effect of plateletderived growth factor in experimental colitis in rats. Orvosi Hetilap 1995; 136: 1059-61.
20. Szabo S, Deng X, Tolstanova G, et al. Angiogenic and antiangiogenic therapy for gastrointestinal ulcers: New challenges for rational therapeutic predictions and drug design. Curr Pharm Des 2011; 17: 1633-42.
21. Paunovic B, Deng X, Khomenko T, et al. Molecular mechanisms of basic fibroblast growth factor effect on healing of ulcerative colitis in rats. J Pharmacol Exp Ther 2011; 339: 430-7.
22. Matsuura M, Okazaki K, Nishio A, et al. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology 2005; 128: 975-86.
23. Kojima T, Watanabe T, Hata K, Nagawa H. Basic fibroblast growth factor enema improves experimental colitis in rats. Hepatogastroenterolog 2007; 54: 1373-7.
24. Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. Rac-1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3-K/Akt pathway. J Biol Chem 2011; 286: 9097-106.
25. Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathological VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood 2011; 117: 1751-60.
26. Tolstanova G, Deng XM, French SW, et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 2012; 92: 9-21.
27. McLaren WJ, Anikijenko P, Thomas SG, Delaney PM, King RG. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci 2002; 47: 2424-33.
28. Tarnawski A, Coron E, Mosnier JF, et al. In-vivo detection by confocal endomicroscopy of two distinct structural abnormalities in angioarchitecture and increased VP in colonic mucosa of patients with IBD in remission: mechanistic implications. Gastroenterology 2009; 136: A112.
29. Folkman J, Shin Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
30. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-3.
31. Szabo S. Pharmacological modulation of cellular, vascular and motility factors. In: Garner A, Whittle BJR, Eds. Drug Therapy of Gastrointestinal Ulceration. London: John Wiley; 1989; pp. 205-20.
32. Szabo S, Shing Y, Folkman J, et al. Angiogenesis and growth factors in ulcer healing. In: Fan TPD, Kohn EC, Eds. The New Angiotherapy. New Jersey: Humana Press; 2001; pp.199-211.
33. Szabo S, Vincze, A. Growth factors in ulcer healing: Lessons from recent studies. J Physiol (Paris) 2000; 94: 77-81.
34. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997; 18: 4-25.
35. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011; 27: 563-84.
36. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006; 169: 2014-30.
37. Danese S, Sans M, Spencer DM, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007; 56: 855-62.
38. Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun 2006; 350: 147-50.
39. Tolstanova G, Deng X, Khomenko T, et al. Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis. Life Sci 2010; 88: 74-81.
40. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007; 2: 251-75.
41. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med 2008; 8: 754-67.
42. Hoenig MR, Bianchi C, Sellke FW. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis. Curr Drug Targets 2008; 9: 422-35.
43. Deng X, Szabo S, Khomenko T, Jadus MR, Yoshida M. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J Pharmacol Exp Ther 2004; 311: 982-8.
44. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
45. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGF-B and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008; 8: 942-56.
46. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-83.
47. Satoh H, Sato F, Takami K, Szabo S. New ulcerative colitis model induced by sulfhydryl blockers in rats and the effects of antiinflammatory drugs on the colitis. Jpn J Pharmacol 1997; 73: 299-309.
48. Antoniades HN, Hunkapiller MW. Human platelet-derived growth factor (PDGF): amino terminal amino acid sequence. Science 1983; 220: 963-5.
49. Nagai MK, Embil JM. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2002; 2: 211-8.
50. Sikiric P, Seiwerth S, Mise S, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns 2003; 29: 323-34.
51. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011; 17: 1612-32.
52. Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Curr Pharm Des 2010; 16: 1224-34.
53. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-inducedcolonic damage in rats. J Pharmacol Exp Ther 1994; 272: 417-22.
54. Sandor Zs, Vincze A, Jadus MR, Dohoczky Cs, Erceg D, Szabo S. The protective effect of newly isolated peptide PL-10 in the iodoacetamide colitis model in rats. Gastroenterology 1997; 112: A400.
55. Khomenko T, Szabo S, Deng XM, Sandor Z, Gombos Z, Yoshida M. Cell proliferation, transcription factor Egr-1 and growth factors in experimental ulcerative colitis after treatment with PL 14736: In vitro and in vivo studies. Gastroenterology, 2003; 124: A493.
56. Veljaca M, Krnic Z, Brajsa K, et al. The development of PL 14736 for treatment of inflammatory bowel disease. IUPHAR-GI Section Symposium, Honolulu, Hawaii 2002; 13-15 July, 0-32.
57. Veljaca M, Pavic Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut 2003; 51(Suppl III), A309.
58. Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: Stable gastric pentadecapeptide BPC 157. Curr Med Chem 2012; 19: 126-32.
59. Veljaca M. Anti-inflammatory peptides and proteins in inflammatory bowel disease. Curr Opin Investig Drugs 2001; 2: 1387-94.
60. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol 2009; 60(Suppl 7): 191-6.
61. Leone DP, Srinivasan K, Brakebusch C, McConnell SK. The Rho GTPase Rac1 is required for proliferation and survival of progenitors in the developing forebrain. Dev Neurobiol 2010; 70: 659-78.
62. Castilho RM, Squarize CH, Leelahavanichkul K, Zheng Y, Bugge T, Gutkind JS. Rac1 is required for epithelial stem cell function during dermal and oral mucosal wound healing but not for tissue homeostasis in mice. PLoS One 2010; 5: e10503.
63. Rao JN, Liu SV, Zou T, et al. Rac1 promotes intestinal epithelial restitution by increasing Ca2+ influx through interaction with phospholipase C-(gamma)1 after wounding. Am J Physiol Cell Physiol 2008; 295: C1499-509.
64. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann N Y Acad Sci 2008; 1123: 134-45.
65. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008; 11: 109-19.
66. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060-73.
67. Foitzik T, Kruschewski M, Kroesen A, Buhr HJ. Does microcirculation play a role in the pathogenesis of inflammatory bowel diseases? Answers from intravital microscopic studies in animal models. Int J Colorectal Dis 1999; 14: 29-34.
68. Danese S. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol 2007; 23: 384-9.
69. Herbert SP, Stainier DY. Molecular control of endothelial cell behavior during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011; 12: 551-64,.
70. Raithel M, Matek M, Baenkler HW, Hahn EG. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995; 108: 127-33.
71. Winterkamp S, Weidenhiller M, Otte P, Stolper J, Raithel M. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 3071-7.
72. Rijnierse A, Redegeld FA, Blokhuis BR, et al. Ig-free light chains play a crucial role in murine mast cell-dependent colitis and are associated with human inflammatory bowel diseases. J Immunol. 2010; 185: 653-9.
73. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49: 253-78.
74. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol 2006; 147(Suppl 1): S127-35.
75. Clough GF, Bennett AR, Church MK. Effects of H1 antagonists on the cutaneous vascular response to histamine and bradykinin: a study using scanning laser Doppler imaging. Br J Derm 1998; 138: 806-14.
76. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 2009; 335: 249-59.
77. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, et al. VEGF-induced vascular permeability is mediated by FAK. Dev Cell 2012; 22: 146-57.
78. Zhao D, Qin L, Bourbon PM, James L, Dvorak HF, Zeng H. Orphan nuclear transcription factor TR3/Nur77 regulates microvessel permeability by targeting endothelial nitric oxide synthase and destabilizing endothelial junctions. Proc Natl Acad Sci USA 2011; 108: 12066-71.
79. Di Sabatino A, Ciccocioppo R, Armellini El. Serum bFGF and VEGF correlate respectively with bowel wall thickness in Crohn's disease. Inflamm Bowel Dis 2004; 10: 573-7.
80. Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 504-8.
81. Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003; 18: 418-22.
82. Sandor Zs, Szabo S, Zagoni T, Tulassay Zs. Differential changes of VEGF and PDGF in human serum and biopsy samples in UC and Crohn's disease. Gastroenterology 1998; 114: A1075
83. Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S. Altered angiogenic balance in UC: a key to impaired healing? Biochem Biophys Res Commun 2006; 350: 147-50.
84. Tolstanova G, Khomenko T, Deng X, Szabo S, Sandor Z. New molecular mechanisms of the unexpectedly complex role of VEGF in ulcerative colitis. Biochem Biophys Res Commun 2010; 399: 613-6.
85. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4: 915-24.
86. Eliceiri BP, Puente XS, Hood JD, et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 2002; 157: 149-60.
87. Gao X, Kouklis P, Xu N, et al. Reversibility of increased microvessel permeability in response to VE-cadherin disassembly. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1218-25.
88. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann N Y Acad Sci 2008; 1123: 134-45.
89. Gavard J and Gutkind JS VEGF controls endothelial-cell permeability by promoting the α-arrestin-dependent endocytosis of VEcadherin. Nat Cell Biol 2006; 8: 1223-1234.
90. Sawant DA, Tharakan B, Adekanbi A, Hunter FA, Smythe WR, Childs EW. Inhibition of VE-cadherin proteasomal degradation attenuates microvascular hyperpermeability. Microcirculation 2011; 18: 46-55.